My opinion is durations beyond 12-weeks could just as likely show lower SVR rates than higher. This is partially based on my on own views that the window of activity in oral therapy is much shorter than with interferon-based. Longer durations didn't boost SVR rates when the Sofo/Riba combo was tested in GT1. This study may have been in nulls so perhaps not a fair comparison.
Do you recall GILD releasing SVR4 rates for either the POSITRON or FISSION studies? Do you recall seeing this data released at a conference poster presentation?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.